AEI Clients in the COVID-19 Fight: Takeda
Takeda developing plasma therapy for treating COVID-19 patients.
Takeda is developing a plasma-derived hyperimmune globulin therapy — TAK-888 — for COVID-19. TAK-888 could be used to treat severely ill patients and could potentially help at-risk health care workers develop immunity.